Bacteria Clinical Trials Immune Response Protein 
Drug Discovery World
JUNE 19, 2024
Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise and destroy cancer cells.
Pfizer
FEBRUARY 16, 2023
These study participants, representing approximately half of the total recruited participants in the trial, are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-party clinical trial site operator.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 28, 2024
We have identified markers for vascular damage in children admitted to hospital with fever and suspected infection, and the protein-signalling pathways associated with this in the cells. The drug we have developed targets these interactions, to restore the function of vascular endothelial cells.”
Drug Discovery World
JANUARY 24, 2023
Dr Kaustav Das Gupta and Professor Matt Sweet from UQ’s Institute for Molecular Bioscience discovered that a molecule derived from glucose in immune cells can both stop bacteria growing and dampen inflammatory responses. Coli bacteria from growing,” Dr Das Gupta said. “It
Camargo
JULY 27, 2021
Viruses and bacteria can be first modified to prevent them from causing infectious diseases and then implemented into human tissues as therapeutic gene vectors. While most gene therapy clinical studies are ongoing, a number of products are in advanced clinical development, and several are approved by FDA.
pharmaphorum
DECEMBER 15, 2020
million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials. Proceeds will advance the clinical development of MinervaX’s novel GBS vaccine through phase 2 clinical trials, as well as manufacturing and regulatory preparation for phase 3.
XTalks
JANUARY 20, 2021
While diseases like celiac are associated with inappropriate activation of the immune system triggered by food antigens, this is not the case in IBS. In a normal, healthy intestine, foods do not trigger immune responses and so in a patient with IBS, something else must activate the response. Mouse and Human Studies.
Expert insights. Personalized for you.
52 
Let's personalize your content